抗体偶联药物治疗急性髓系白血病的研究进展  

Advances of antibody drug conjugate for acute myeloid leukemia

作　　者：王玉娇 杨锦才 赵丽 WANG Yujiao;YANG Jincai;ZHAO Li(The First School of Clinical Medicine,Lanzhou University,Gansu Lanzhou 730000,China;Gansu Provincial Clinical Medical Research Center for Molecular Diagnosis and Treatment of Hematological Diseases,Gansu Lanzhou 730000,China)

机构地区：[1]兰州大学第一临床医学院,甘肃兰州730000 [2]甘肃省血液病分子诊断与治疗临床医学研究中心,甘肃兰州730000

出　　处：《现代肿瘤医学》2025年第6期1062-1068,共7页Journal of Modern Oncology

摘　　要：急性髓系白血病(acute myeloid leukemia, AML)是成人最常见的白血病之一,主要治疗方式为常规化疗。尽管标准化疗方案的完全缓解率(complete remission rate, CRR)较高,但易复发、易耐药等特点导致患者预后差。因此迫切需要更为安全有效的治疗方法提高患者生存率。作为单克隆抗体与细胞毒性药物的结合物,抗体偶联药物(antibody drug conjugate, ADC)是一种高效、特异的新型免疫靶向治疗药物,可为AML提供新的治疗策略。目前已有针对AML的ADC应用于临床治疗,但多数还处于临床试验中。该文就ADC在AML中的研究进展进行综述。Acute myeloid leukemia(AML)is among the most prevalent types of leukemia in adults,and its primary treatment modality involves conventional chemotherapy.Despite the high complete remission rate(CRR)associated with standard chemotherapy regimens,the propensity for relapse and drug resistance contributes to a poor prognosis for patients.Consequently,there is an urgent need for safer and more effective therapeutic approaches to enhance patient survival rate.Antibody drug conjugates(ADC),which represent a novel class of immune-targeted therapeutic agents that combine monoclonal antibodies with cytotoxic drugs,offer a highly efficient and specific treatment option that may present new strategies for managing AML.Several ADC targeting AML have already been employed in clinical treatment,with many still undergoing clinical trials.This review provides an overview of the research progress on ADC in the context of AML treatment.

关 键 词：急性髓系白血病 免疫靶向治疗 抗体偶联药物 

分 类 号：R730.5[医药卫生—肿瘤]